Compare Ascendis Pharma A/S (ASND) vs Enovix Corporation (ENVX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Enovix Corporation — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Enovix Corporation trades at $5.22 (market cap $1.14B). The key difference: Ascendis Pharma A/S is far larger — about 15.6× Enovix Corporation's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Enovix Corporation nearer its low. Which is the better fit depends on your goals.
| ASND | ENVX | |
|---|---|---|
Market Cap | $17.74B | $1.14B |
Sector | Health | Technology |
52-Week High | $277.18 | $15.93 |
52-Week Low | $163.32 | $4.84 |
Enterprise Value | $18.11B | $1.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
ENVX trades at $5.20, down 3.7% on the day, with a bearish technical signal from moving averages. The company reported Q1 2026 revenue above guidance and an EPS beat of -$0.14 versus -$0.15 expected, but net losses remain substantial at -$156.74M for 2025. Positive developments include the appointment of a former Apple operations leader as COO to scale manufacturing.
The outlook is mixed: strong analyst buy consensus (75%) and a $12.75 price target suggest significant upside, but high cash burn, negative margins, and persistent losses pose substantial execution risks. Investor sentiment hinges on successful production scaling and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Enovix Corporation
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →
